Exabis Library
Welcome to the e-CCO Library!
P336: Can Mesenchymal Stem Cell (MSC) apoptosis be used as a biomarker for treatment success in perianal fistulising Crohn’s Disease (pCD)? Findings from a prospective pilot study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P336: Endoscopic scores as predictors of treatment failure in Ulcerative Colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P336: French prospective, longitudinal observational study of the therapeutic management of mild to moderate ulcerative colitis (Optimum study): follow-up at 3 years
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P336: Is endoscopy necessary to measure disease activity in ulcerative colitis: A systematic narrative review
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P336: Safety of anti-TNF treatment in older IBD patients: a systematic review and meta-analysis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P337 Usefulness of drug-level monitoring in therapeutic guidance in patients with ulcerative colitis on anti-TNF-α maintenance therapy
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P337: Anti-TNFalpha therapy is associated with rapid reduction of circulating monocyte numbers and blunted monocyte pro-inflammatory response in patients with Crohn’s disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P337: Developing Preliminary MRI-based Classifier for Perianal Fistulizing Crohn's Disease by Using Deep Convolutional Neural Networks
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P337: Early infliximab clearance predicts remission in children with Crohn’s Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P337: Efficacy of intravenous cyclosporine in fulminant steroid-refractory ulcerative colitis with massive bleeding: a retrospective, observational study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P337: Low seroprevalence of celiac disease in a large screening study in unselected Swiss IBD cohort patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P337: Switching from originator infliximab to CT-P13: single-centre experience from the UK
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P337: Therapeutic drug monitoring: standardization of Promonitor Quick IFX and Promonitor Quick ADL point of care tests with WHO International Standards for the quantification of infliximab and adalimumab in whole blood and serum
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P338 The effectiveness of a standardised biologic care pathway in the management and treatment of inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P338: Early proactive drug monitoring strategy of infliximab as monotherapy for inflammatory bowel disease in paediatric patients is associated with good sustained clinical remission
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P338: effectiveness and safety of biological therapies in elderly inflammatory bowel diseases patients results from a multi center study of Geteccu
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P338: Long-term complications in patients with fistulising Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P338: Outcome of hospitalised patients with inflammatory bowel disease complicated by Clostridium difficile infection: Results from a tertiary referral centre
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P338: Rate and predictors of mucosal healing in patients with ulcerative colitis treated with thiopurines: results of a multicentric cohort study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P338: Transmural healing is not associated with less disability than complete endoscopic mucosal healing: a prospective study in a patient with Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM